Biogen and Denali Therapeutics disclosed that their experimental Parkinson’s therapy targeting LRRK2 failed to slow the degenerative disease in a randomized trial. The study enrolled 648 adults with Parkinson’s and compared the investigational pill against placebo, aiming to test the broader rationale that LRRK2 inhibition could benefit all patients. The companies’ result undercuts a hypothesis driven by prior genetic and mechanistic work linking LRRK2 mutations to a rare inherited form of Parkinson’s and by earlier studies suggesting blocking the target might help in general disease contexts. Thursday’s outcome represents a setback for the approach that had attracted excitement among advocates and researchers. The report provided high-level trial framing but did not detail whether specific subgroups showed signals. Still, the negative primary readout is likely to redirect near-term investment attention and clinical strategy across LRRK2 programs. For Parkinson’s drug developers, the failure reinforces the challenge of translating target biology into disease modification endpoints in late-stage neurodegeneration trials.